Alembic Pharmaceuticals Limited has announced receiving tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Palbociclib Capsules, 75 mg, 100 mg, and 125 mg.
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), lbrance Capsules, 75 mg, 100 mg, and 125 mg, of Pfizer Inc.
For women
Palbociclib Capsule is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or in combination with fulvestrant in women with disease progression following endocrine therapy.
Palbociclib Capsules, 75 mg, 100 mg, and 125 mg have an approximate market size of US$ 624 million for 12 months ending June 2020 according to IQVIA.
Alembic is currently in litigation with Pfizer in a district court and launch of the product will depend on litigation outcome.
At present, Alembic, a vertically integrated research and development pharmaceutical company, has a total of 135 ANDA approvals (117 final approvals and 18 tentative approvals) from USFDA.
(With inputs from The OnLook News Research Bureau)
If you like this article and if you feel it will be helpful for others to understand on the subject, please share it. You can also follow us on Twitter, Facebook & Linkedin
![](https://theonlook.com/wp-content/uploads/2023/10/For-wordpress.jpg")
Read more: Aster Labs unveils Digital Pathology Solution approved by USFDA
){kind=link}